Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1521-1540 of 2,251 trials

Nivolumab and Entinostat for High-Risk Cancers in Kids

We are exploring a new treatment combining Nivolumab and Entinostat for children and adolescents with hard-to-treat cancers. The study aims to see if this combination can help those with specific tumor characteristics.

Relapsed or Refractory High-Risk Malignant Disease>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPediatrics

Heart Health: Apixaban vs. Warfarin Study

We are comparing two medications to see which is more effective in resolving blood clots in patients with left ventricular thrombus after a heart attack. We're also looking at safety and bleeding risks associated with each treatment.

Acute Myocardial InfarctionLeft Ventricular Thrombosis3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Metastatic Colorectal Cancer: Valproic Acid and Standard Treatment

We are studying a new combination of Valproic acid with standard therapies for patients with metastatic colorectal cancer who have already been treated. The goal is to see if this combination improves survival and quality of life compared to standard treatment alone.

Metastatic Colorectal Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

BCG Vaccination: Understanding Immune Response

We are studying how pre-vaccination immune status affects the response to the BCG vaccine. This research may help improve vaccination strategies by identifying key immune factors.

Healthy Participants>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

Epcoritamab for Relapsed Large B-Cell Lymphoma

We are studying the effectiveness of Epcoritamab as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma. This trial aims to see how well it works and how safe it is compared to other treatments.

Diffuse Large B-cell Lymphoma1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Ewing's Sarcoma: Naxitamab Treatment Study

We are evaluating the safety and effectiveness of naxitamab added to standard chemotherapy for patients with refractory Ewing's sarcoma. This study aims to see if this combination can improve treatment outcomes.

Ewing's Sarcoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Low Ovarian Reserve: Factor-Rich Plasma Treatment

We are studying whether Factor-Rich Plasma injections can improve ovarian function and increase pregnancy rates in women with low ovarian reserve. This trial will also monitor any potential complications from the treatment.

Low Ovarian Reserve1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGynecology and ObstetricsInternal Medicine

AMG 193 for Advanced Non-Small Cell Lung Cancer

We are studying a new treatment, AMG 193, for patients with advanced non-small cell lung cancer that has a specific genetic deletion. The trial aims to evaluate its safety and effectiveness compared to existing options.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced NSCLC: MCLA-129 Treatment Study

We are evaluating a new bispecific antibody, MCLA-129, for patients with advanced non-small cell lung cancer. The study aims to assess its effectiveness and safety compared to standard treatments.

Solid TumorsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Advanced Lung Cancer: ABBV-400 and Budigalimab Study

We are testing a new treatment combining ABBV-400 and Budigalimab for adults with advanced non-squamous lung cancer who haven't had prior treatment. The goal is to see how safe it is and how well it works.

Advanced Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

New Treatment for Primary CNS Lymphoma: Optimizing MATRix

We are studying a modified treatment approach for patients with newly diagnosed primary CNS lymphoma to see if it improves survival and quality of life compared to standard therapy. This trial aims to find a safer and effective way to induce remission before further treatment.

Primary Central Nervous System Lymphoma (PCNSL)>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Breast Cancer: Shorter Hormone Therapy Duration

We are studying whether limiting hormone therapy to 2 years is effective for women with hormone-sensitive breast cancer at very low risk of recurrence. This trial aims to assess the safety and quality of life during and after treatment.

Localized Luminal A Breast Cancer in Post-Menopausal Women>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyOncology

Giant Cell Arteritis and Rheumatoid Arthritis: PET/CT Imaging Study

We are testing a new imaging method to see inflamed arteries in giant cell arteritis and inflamed joints in rheumatoid arthritis. This study aims to improve how we visualize and understand these conditions.

Giant Cell ArteritisRheumatoid Arthritis>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyRheumatology

Giant Cell Arteritis: Imaging Study with [18F]fluor-PEG-folate

We are investigating how well a special imaging technique shows changes in arteries of patients with giant cell arteritis before and after treatment. This may help us understand the disease better and improve future care.

Giant Cell Arteritis6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementRheumatology

Duchenne Muscular Dystrophy: SGT-003 Gene Therapy

We are studying a new gene therapy to see if it is safe and effective for males with Duchenne Muscular Dystrophy. The trial will assess improvements in muscle function and other health measures after a single intravenous dose.

Duchenne Muscular Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteNeurology

Psoriatic Arthritis and Axial Spondyloarthritis: Sonelokimab Study

We are exploring how sonelokimab affects disease activity in patients with active psoriatic arthritis or axial spondyloarthritis. This study will help us understand its potential benefits and safety.

Axial SpondyloarthritisPsoriatic Arthritis3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicineRheumatology

Acute Myeloid Leukemia: Low Intensity Therapy Study

We are exploring whether a gentler treatment approach helps patients with relapse or refractory acute myeloid leukemia live longer and feel better compared to stronger therapies.

Acute Myeloid LeukemiaConfirmation phase (III)No PlaceboStandard MedicinesOncology

Familial Hypercholesterolemia: Inclisiran vs. Alirocumab

We are comparing two new treatments, inclisiran and alirocumab, to standard therapy for children with heterozygous familial hypercholesterolemia. The goal is to see which treatment better lowers cholesterol levels and improves quality of life.

Heterozygous Familial Hypercholesterolemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCardiologyEndocrinology

Severe Vitamin D Deficiency: New Treatment Study

We are investigating a new treatment for people with severe vitamin D deficiency to see if it effectively raises vitamin D levels compared to another option. The study will also look at safety and patient satisfaction.

Severe Vitamin D Deficiency≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyInternal Medicine

APL-101 for Advanced Non-Small Cell Lung Cancer

We are studying a new treatment, APL-101, for patients with advanced solid tumors, including non-small cell lung cancer with specific genetic mutations. The trial aims to assess its safety and effectiveness, as well as find the best dose.

Non-Small Cell Lung CancerCentral Nervous System NeoplasmSolid Tumors>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology